Welcome to our dedicated page for Optimi Health news (Ticker: OPTH), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Optimi Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Optimi Health's position in the market.
Optimi Health (NASDAQ: OPTH), a commercial-stage manufacturer of regulated psychedelic drug products, completed a production run of a naturally derived psilocybin extract measuring about 6% psilocybin, its highest-purity botanical extract to date.
The extract will support Australian treatment-resistant depression prescriptions, upcoming European clinical research, and ongoing product development, while aggregate Scheme data to December 2025 report no serious adverse events.
Optimi Health (NASDAQ: OPTH) closed an oversubscribed underwritten public offering of 2,400,000 common shares at US$6.25 per share, raising US$15 million in gross proceeds in connection with its uplisting to the Nasdaq Capital Market.
The shares began trading on Nasdaq on May 20, 2026 under OPTH and continue on the CSE as OPTI. The underwriter received 96,000 warrants exercisable at US$7.50 per share until May 21, 2031.
Optimi Health (Nasdaq: OPTH) priced an oversubscribed underwritten public offering of 2,400,000 common shares at US$6.25 per share, for expected gross proceeds of about US$15 million, alongside an uplisting to the Nasdaq Capital Market effective May 20, 2026.
The company also completed a 1‑for‑30 share consolidation on May 19, 2026, leaving approximately 3,225,881 shares outstanding before the offering and any underwriter option exercises.